450 related articles for article (PubMed ID: 25791754)
1. Biomarkers for immunotherapy in genitourinary malignancies.
Slovin SF
Urol Oncol; 2016 Apr; 34(4):205-13. PubMed ID: 25791754
[TBL] [Abstract][Full Text] [Related]
2. The immunotherapy revolution in genitourinary malignancies.
U Gandhy S; Madan RA; Aragon-Ching JB
Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
[TBL] [Abstract][Full Text] [Related]
3. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for genitourinary cancer: state of the art and new perspectives.
Cattrini C; Dellepiane C; Cavo A; Buzzatti G; Tolomeo F; Messina C; Boccardo F
Anticancer Drugs; 2016 Aug; 27(7):585-99. PubMed ID: 27183027
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy in genitourinary malignancies.
Hoffman-Censits J; Wilde L
Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
[TBL] [Abstract][Full Text] [Related]
6. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
7. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
Dallos MC; Drake CG
Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in genitourinary malignancies.
Mehta K; Patel K; Parikh RA
J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
11. Novel immunotherapies in GU malignancies.
Drakaki A; McDermott DF
Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
[TBL] [Abstract][Full Text] [Related]
12. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T; Montironi R; Lopez-Beltran A; Van Leenders G; Allory Y; De Ridder D; Claessens F; Kockx M; Akand M; Joniau S; Netto G; Libbrecht L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):216-227. PubMed ID: 29032188
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for genitourinary malignancies in the here and now!
Slovin SF
Urol Oncol; 2016 Apr; 34(4):169-70. PubMed ID: 26705103
[No Abstract] [Full Text] [Related]
14. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in genitourinary cancers: achievements and perspectives.
Xylinas E; Roumiguié M; Sargos P
World J Urol; 2021 May; 39(5):1317. PubMed ID: 34003335
[No Abstract] [Full Text] [Related]
16. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Klein O; Kee D; Gao B; Markman B; da Gama Duarte J; Quigley L; Jackett L; Linklater R; Strickland A; Scott C; Mileshkin L; Palmer J; Carlino M; Behren A; Cebon J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782426
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
Marciscano AE; Madan RA
Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Chalfin HJ; Pramparo T; Mortazavi A; Niglio SA; Schonhoft JD; Jendrisak A; Chu YL; Richardson R; Krupa R; Anderson AKL; Wang Y; Dittamore R; Pal SK; Lara PN; Stein MN; Quinn DI; Steinberg SM; Cordes LM; Ley L; Mallek M; Sierra Ortiz O; Costello R; Cadena J; Diaz C; Gulley JL; Dahut WL; Streicher H; Wright JJ; Trepel JB; Bottaro DP; Apolo AB
Clin Cancer Res; 2021 Mar; 27(5):1391-1398. PubMed ID: 33262136
[TBL] [Abstract][Full Text] [Related]
19. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
McGregor BA; Campbell MT; Xie W; Farah S; Bilen MA; Schmidt AL; Sonpavde GP; Kilbridge KL; Choudhury AD; Mortazavi A; Shah AY; Venkatesan AM; Bubley GJ; Siefker-Radtke AO; McKay RR; Choueiri TK
Cancer; 2021 Mar; 127(6):840-849. PubMed ID: 33216356
[TBL] [Abstract][Full Text] [Related]
20. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
